Vertex Pharmaceuticals (VRTX) Change in Account Payables (2009 - 2026)

Vertex Pharmaceuticals' Change in Account Payables history runs 18 years deep, the most recent figure standing at $35.6 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 35.88% year-over-year to $35.6 million in Q1 2026; TTM through Mar 2026 was $46.2 million, a 38.89% decrease from a year earlier, with the FY2025 full-year figure at $36.8 million, down 25.66% from the prior year.
• Change in Account Payables declined to $35.6 million in Q1 2026 per VRTX's latest filing, from $38.3 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $159.9 million in Q4 2022 and bottomed at -$69.9 million in Q3 2022.
• The 5-year median for Change in Account Payables is $9.2 million (2023), against an average of $17.1 million.
• Across the five-year window, Change in Account Payables plunged 3139.13% in 2022 and surged 26100.0% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $159.9 million in 2022, then slumped by 119.89% to -$31.8 million in 2023, then surged by 126.42% to $8.4 million in 2024, then jumped by 355.95% to $38.3 million in 2025, then decreased by 7.05% to $35.6 million in 2026.
• Per Business Quant, the three latest VRTX Change in Account Payables figures stand at $35.6 million (Q1 2026), $38.3 million (Q4 2025), and -$35.3 million (Q3 2025).